Brainsway Ltd
$ 14.43
0.14%
09 Jun - close price
- Market Cap 556,884,000 USD
- Current Price $ 14.43
- High / Low $ 14.74 / 13.93
- Stock P/E 63.14
- Book Value 1.99
- EPS 0.22
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.13 %
- 52 Week High 17.35
- 52 Week Low 5.33
About
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Analyst Target Price
$16.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-11 | 2025-11-11 | 2025-08-13 | 2025-05-13 | 2025-03-11 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-03-06 | 2023-11-15 | 2023-08-09 |
| Reported EPS | 0.06 | 0.0638 | 0.04 | 0.05 | 0.02 | 0.04 | 0.02 | 0.04 | 0.0067 | 0.0076 | -0.02 | -0.1 |
| Estimated EPS | 0.05 | 0.0456 | 0.05 | 0.03 | 0.0233 | 0.02 | 0.01 | -0.01 | -0.02 | -0.01 | -0.03 | -0.09 |
| Surprise | 0.01 | 0.0182 | -0.01 | 0.02 | -0.0033 | 0.02 | 0.01 | 0.05 | 0.0267 | 0.0176 | 0.01 | -0.01 |
| Surprise Percentage | 20% | 39.9123% | -20% | 66.6667% | -14.1631% | 100% | 100% | 500% | 133.5% | 176% | 33.3333% | -11.1111% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BWAY
2026-06-09 11:58:30
BrainsWay Ltd. presented positive 12-month data on its accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol for Major Depressive Disorder, showing over 80% remission rates and reduced functional impairment. The SWIFT protocol, cleared by the FDA in September 2025, significantly cuts down clinic visits. The company is experiencing strong financial performance with shares up 162% over the past year and reported a 29% revenue growth in the last twelve months, alongside a recent strategic investment in Hopemark Health.
2026-06-09 11:39:30
BrainsWay presented promising 12-month durability data for its SWIFT™ Accelerated Deep TMS protocol at the Clinical TMS Society Annual Meeting. The data indicated over an 80% remission rate for Major Depressive Disorder (MDD) patients one year post-treatment, with severe functional impairment dropping from 85% to 0%. This study validates the sustained clinical benefits and functional improvements of the SWIFT™ protocol, which reduces treatment visits compared to traditional methods.
2026-06-06 16:39:32
This article provides a technical analysis and stock price forecast for Brainsway Ltd (BWAY), indicating a "Sell" consensus based on various technical indicators as of June 5, 2026. While the stock's RSI suggests a neutral condition, the MACD and several moving averages point towards a sell signal. Key support and resistance levels are identified, with the price currently trading above its 200-day moving average, signaling a long-term bullish trend despite short-term sell indicators.
2026-06-06 05:09:57
MEITAV INVESTMENT HOUSE LTD has acquired 2,532,352 shares of BrainsWay Ltd for $13.55 per share, representing 0.37% of MEITAV's portfolio. BrainsWay Ltd, an Israeli company specializing in Deep TMS technology for mental health, is currently considered significantly overvalued despite its innovative solutions and strong balance sheet, with a GF Value of $7.07 against its stock price of $13.55. MEITAV's strategic investment aligns with its focus on high-growth potential in the medical technology sector, banking on BrainsWay's long-term impact.
2026-06-03 20:10:54
Brainsway Ltd.'s Chief Scientist, Dr. Roth Yiftach, sold 7,000 Ordinary Shares in open-market transactions on June 1-2, 2026, at prices ranging from NIS 42.0035 to NIS 43.64 per share. Following these sales, Dr. Yiftach directly holds 1,072,305 Ordinary Shares, which includes jointly held shares and 5,000 unvested Restricted Stock Units set to vest through March 2030. The transactions were reported in a Form 4 filing, indicating a neutral sentiment impact.
2026-06-03 11:10:54
MEITAV affiliates have reported significant stakes in Brainsway Ltd. (NASDAQ: BWAY) through an amended Schedule 13G/A filing. As of June 1, 2026, MEITAV Investment House Ltd. holds 6.31% of ordinary shares (2,532,352 shares) and MEITAV Provident Funds & Pension Ltd. holds 5.16% (2,069,247 shares). The filing emphasizes that these holdings are managed by subsidiaries making independent voting and investment decisions, disclaiming the formation of any Section 13(d) group.
